These findings reveal that loss of NOTCH2 activates the TRAF6/AKT axis and promotes metastasis in NPC, suggesting that NOTCH2 may represent a therapeutic target for the treatment of NPC. This evidence concerns the gene NOTCH2 and nasopharyngeal carcinoma.